Suboxone Related Published Studies
Well-designed clinical trials related to Suboxone (Buprenorphine / Naloxone)
Cocaine use reduction with buprenorphine (CURB): rationale, design, and
methodology. [2013]
A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. [2011.07.12]
Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. [2011.03]
The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone. [2011.01]
Induction of opioid-dependent individuals onto buprenorphine and
buprenorphine/naloxone soluble-films. [2011]
Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. [2010.09]
Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. [2010.07]
Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. [2010.05]
Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. [2010.04]
Buprenorphine tapering schedule and illicit opioid use. [2009.02]
Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. [2008.11.05]
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. [2008.07]
Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. [2008.03]
A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. [2007.12]
A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. [2007.05]
Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. [2007.02]
Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. [2006.12]
Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. [2006.03.15]
Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. [2005.08.24]
A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. [2005.08]
The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? [2005.07]
A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. [2004.05.10]
Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. [2004]
Controlled trial of maintenance treatment of intravenous buprenorphine dependence. [2003.10]
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. [2003.09.04]
Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. [2003.09]
Effects of buprenorphine/naloxone in opioid-dependent humans. [2001.03]
Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. [2000.02.01]
Naltrexone shortened opioid detoxification with buprenorphine. [1999.10.01]
Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. [1999.07]
Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. [1998.03.01]
Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. [1997.04.14]
Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance. [1994.11]
[Risk evaluation of oxygen desaturation after buprenorphine or morphine administration during the early postoperative period] [1994]
Buprenorphine alone and in combination with naloxone in non-dependent humans. [1992.08]
Development of buprenorphine for the treatment of opioid dependence. [1992]
[Influence of intrathecal morphine and buprenorphine on EEG and their analgesic effect] [1990.04]
Naloxone suppresses buprenorphine stimulation of plasma prolactin. [1989.04]
Buprenorphine antagonism of ventilatory depression following fentanyl anaesthesia. [1988.08]
Influence of naloxone on the postoperative analgesic and respiratory effects of buprenorphine. [1988]
Well-designed clinical trials possibly related to Suboxone (Buprenorphine / Naloxone)
Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms. [2011.11]
HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. [2010.09.01]
HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. [2010.09]
Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. [2004.02]
Inducing placebo respiratory depressant responses in humans via opioid receptors. [1999.02]
Postoperative analgesia with epidural bupivacaine and low-dose fentanyl--a comparison of two concentrations. [1998.08]
Three methods of opioid detoxification in a primary care setting. A randomized trial. [1997.10.01]
Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. [1996.11]
Other research related to Suboxone (Buprenorphine / Naloxone)
Initial response as a predictor of 12-week buprenorphine-naloxone treatment
response in a prescription opioid-dependent population. [2015]
Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes
among prescription opioid users, heroin users and combination users. [2015]
Patient perspectives on buprenorphine/naloxone: a qualitative study of retention
during the starting treatment with agonist replacement therapies (START) study. [2014]
A randomized trial of cognitive behavioral therapy in primary care-based
buprenorphine. [2013]
Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid
analgesic, heroin, and combined users: findings from starting treatment with
agonist replacement therapies (START). [2013]
HIV testing and sexual risk reduction counseling in office-based
buprenorphine/naloxone treatment. [2013]
Buprenorphine implants for treatment of opioid dependence: randomized comparison
to placebo and sublingual buprenorphine/naloxone. [2013]
Methadone and buprenorphine-naloxone are effective in reducing illicit
buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a
randomized trial. [2013]
Patient characteristics associated with buprenorphine/naloxone treatment outcome
for prescription opioid dependence: Results from a multisite study. [2013]
A randomized trial of cognitive behavioral therapy in primary care-based
buprenorphine. [2013]
Buprenorphine/Naloxone and methadone effects on laboratory indices of liver
health: a randomized trial. [2013]
Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent
Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058. [2012]
Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent
youth. [2012]
Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. [2011.11]
A case series of buprenorphine/naloxone treatment in a primary care practice. [2011.10]
Bethanechol for buprenorphine-related urinary hesitancy: a case series. [2011.09]
Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. [2011.09]
Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058. [2011.08.16]
Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. [2011.08]
Policy implications of integrating buprenorphine/naloxone treatment and HIV care. [2011.03]
Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. [2011.03]
The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. [2011.03]
Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. [2011.03]
Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. [2011.03]
The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. [2011.03]
Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care. [2011.03]
Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. [2011.03]
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. [2011.03]
Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. [2011.03]
The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia. [2011.03]
Participant characteristics and buprenorphine dose. [2011]
The pharmacodynamic and pharmacokinetic profile of intranasal crushed
buprenorphine and buprenorphine/naloxone tablets in opioid abusers. [2011]
The subjective, reinforcing, and analgesic effects of oxycodone in patients with
chronic, non-malignant pain who are maintained on sublingual
buprenorphine/naloxone. [2011]
Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. [2010.11]
A Clinical Trial Comparing Tapering Doses of Buprenorphine with Steady Doses for Chronic Pain and Co-existent Opioid Addiction. [2010.09]
Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. [2010.08.15]
Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone. [2010.07]
Buprenorphine in the treatment of opiate dependence. [2010.06]
Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network. [2010.06]
From research to the real world: buprenorphine in the decade of the Clinical Trials Network. [2010.06]
Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study. [2010.01]
The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. [2010.01]
Effect of cocaine use on buprenorphine pharmacokinetics in humans. [2010.01]
Suboxone (buprenorphine/naloxone) as an agonist opioid treatment in Spain: a budgetary impact analysis. [2010]
Cost-effectiveness of extended buprenorphine-naloxone treatment for
opioid-dependent youth: data from a randomized trial. [2010]
Pain and continued opioid use in individuals receiving buprenorphine-naloxone for
opioid detoxification: secondary analyses from the Clinical Trials Network. [2010]
Improved HIV and substance abuse treatment outcomes for released HIV-infected
prisoners: the impact of buprenorphine treatment. [2010]
Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in
buprenorphine-maintained intravenous heroin abusers. [2010]
Effect of incarceration history on outcomes of primary care office-based
buprenorphine/naloxone. [2010]
Unobserved versus observed office buprenorphine/naloxone induction: a pilot
randomized clinical trial. [2010]
Early experience with Suboxone maintenance therapy in Hungary. [2009.12]
A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine-naloxone combination. [2009.11]
Spotlight on buprenorphine/naloxone in the treatment of opioid dependence. [2009.10.01]
|
